Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Recent Content
- Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis
- Bortezomib Off-Week Regimen Shows Promise for Reducing Toxicity in Multiple Myeloma
- Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
- LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
- A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
- How well do different chatbots respond to multiple myeloma treatment guidelines?
- Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles
- Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis
- Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes